Journal
CLINICAL SCIENCE
Volume 129, Issue 12, Pages 1037-1045Publisher
PORTLAND PRESS LTD
DOI: 10.1042/CS20150451
Keywords
-
Categories
Funding
- American Cancer Society [122437-RP-12-090-01-COUN]
- Department of Defense Breast Cancer Research Program [W81XWH-12-1-0464]
Ask authors/readers for more resources
The small subpopulation of breast cancer cells that possess the capability for self-renewal and formation of secondary tumours that recapitulate the heterogeneity of the primary tumour are referred to as tumour-initiating cells or BCSCs (breast cancer stem cells). The hypoxic tumour microenvironment and chemotherapy actively induce the BCSC phenotype. HIFs (hypoxia-inducible factors) are required and molecular mechanisms by which they promote the BCSC phenotype have recently been delineated. HIF inhibitors block chemotherapy-induced enrichment of BCSCs, suggesting that their use may improve the response to chemotherapy and increase the survival of breast cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available